Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00MJG
|
||||
| Former ID |
DIB019259
|
||||
| Drug Name |
compound 16
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1], [2] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C31H40ClN5O3
|
||||
| InChI |
InChI=1S/C31H39N5O3.ClH/c1-7-8-17-36-29-24(13-10-15-33-29)25(21-11-9-12-22(18-21)39-6)28(30(36)37)35-31(38)34-27-23(19(2)3)14-16-32-26(27)20(4)5;/h9-16,18-20,26,32H,7-8,17H2,1-6H3,(H2,34,35,38);1H
|
||||
| InChIKey |
UXCQVIIRKWYPHK-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Acetyl-CoA acetyltransferase, mitochondrial | Target Info | Inhibitor | [1] | |
| BioCyc Pathway | Isoleucine degradation | ||||
| Glutaryl-CoA degradation | |||||
| Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | |||||
| Superpathway of cholesterol biosynthesis | |||||
| Mevalonate pathway | |||||
| Ketogenesis | |||||
| Ketolysis | |||||
| KEGG Pathway | Fatty acid degradation | ||||
| Synthesis and degradation of ketone bodies | |||||
| Valine, leucine and isoleucine degradation | |||||
| Lysine degradation | |||||
| Tryptophan metabolism | |||||
| Pyruvate metabolism | |||||
| Glyoxylate and dicarboxylate metabolism | |||||
| Propanoate metabolism | |||||
| Butanoate metabolism | |||||
| Terpenoid backbone biosynthesis | |||||
| Metabolic pathways | |||||
| Biosynthesis of antibiotics | |||||
| Carbon metabolism | |||||
| Fatty acid metabolism | |||||
| NetPath Pathway | Leptin Signaling Pathway | ||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| PathWhiz Pathway | Butyrate Metabolism | ||||
| Fatty acid Metabolism | |||||
| Ketone Body Metabolism | |||||
| Lysine Degradation | |||||
| Valine, Leucine and Isoleucine Degradation | |||||
| Pyruvate Metabolism | |||||
| Propanoate Metabolism | |||||
| Circadian clock | |||||
| WikiPathways | Tryptophan metabolism | ||||
| Synthesis and Degradation of Ketone Bodies | |||||
| Metabolism of amino acids and derivatives | |||||
| Fatty acid, triacylglycerol, and ketone body metabolism | |||||
| Fatty Acid Beta Oxidation | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8. Epub 2005 Oct 18.Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor with improved aqueous solubility. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6726). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.